144
Views
31
CrossRef citations to date
0
Altmetric
Research Article

USE OF p53 TRANSGENIC MICE IN THE DEVELOPMENT OF CANCER MODELS FOR MULTIPLE PURPOSES

, , &
Pages 581-593 | Published online: 02 Jul 2009

References

  • Greenblatt MS, Bennett WP, Hollstein M, Harris CC:Mutations in the p53 tumor suppressor gene:clues to cancer etiology and molecular pathogenesis. Cancer Res. 1994;54:4855-4878.
  • Hegi ME, Soderkvist P, Foley JF, Schoonhoven R, Swenberg JA, Kari F, Maronpot R, Anderson MW, Wiseman RW:Characterization of p53 mutations in methylene chloride-induced lung tumors from B6C3F1 mice. Carcinogenesis. 1993;14:803-810.
  • McKenzie KE, Armstrong BA, Chen Y, Nagarajan M, Aldaz CM, Sukumar S:Alterations in the Ha-ras-1 and p53 pathway genes in the progression of N-methyl-N-nitrosourea induced rat mammary tumors. Mol Carcinog. 1997;20:194-203.
  • Kito K, Kihana T, Sugita A, Murao S, Akehi S, Sato M, Tachibanan M, Kimura S, Ueda N:Incidence of p53 and Ha ras gene mutations in chemically induced rat mammary carcinomas. Mol Carcinog. 1996;17:78-83.
  • Erdman SH, Wu HD, Hixson LG, Ahnene DJ, Gerner EW:Assessment of mutations in Ki-ras and p53 in colon cancers from azoxymethane —and dimethylhydrazine —treated rats. Mol Carcinog. 1997;19:137-144.
  • Makino H, Ushijima T, Kakiuchi H, Onda M, Ito N, Sugimara T, Nagao M:Absence of p53 mutations in rat colon tumors induced by 2-amino-6-pyridirado imidazole;2-amino-3-methylimidazoquinoline or 2-amino-1-methyl-6-phenylimidazopyridine. Jpn J Cancer Res. 1994;85:510-514.
  • Condon MS, Kaplan LA, Crivello JF, Horton L, Bosland MC:Mu ltiple pathways of prostate carcinogenesis analyzed by using cultured cells isolated from rats treated with N-methyl-N-nitrosourea and te stosterone. Mol Carcinog. 1999;25:179-186.
  • Van Kranen HJ, de Gruijl FR:Mutations in cancer genes of UV induced skin tumors of hairless mice. J Epidemiol. 1999;(suppl)9:S58-S65.
  • Dumaz N,van Kramen HJ, de Vries A, Berg RJ,Van Kreiji CF, Sarasin A, Daya-Grosjean L, de Gruijl FR:The role of UV-B light in skin carcinogenesis through the analysis of p53 mutations in squamous cell carcinomas of hairless mice. Carcinogenesis. 1997;18:897-904.
  • Ogawa K, Uzvolgyi E, St John MK, de Olivera ML, Arnold L, Cohen SM:Frequent p53 mutations and occasional loss of chromesome 4 in invasive bladder carcinoma induced by OHBBN in B6D2F1 mice. Mol Carcinog. 1998;21:70-79.
  • Masui T, Dong Y, Yamamoto S, Takada N, Nadanishi H, Inada K, Fukushima S, Tatematsu M:p53 mutations in transitional carcinomas of the urinary bladder in rats treated with OHBBN. Cancer Lett. 1996;19:105-112.
  • You M, Candrian U, Maronpot RR, Stoner GD, Anderson MW:Activation of the K-ras gene in spontaneously occurring and chemically induced strain A mouse lung tumors. Proc Natl Acad Sci US A. 1989;86:3070-3074.
  • Herzog CR, Lubet RA, You M:Genetic epigenetic alterations in mouse lung tu mors:implications for cancer chemop revention. J Cell Biochem. 1997;28/29S:49-63.
  • You M, Bergman G:Preclinical and clinical models of lung cancer chemoprevention. Hematol Oncol Clin North Am. 1998;12:1037-1053.
  • Quantanilla M, Haddow S, Jonas D, Jaffe D, Bowden GT, Balmain A:Comaprison of ras activation during epidermal carcinogenesis in vitro and in vivo. Carcinogenesis. 1991;12:1875-1883.
  • Brown JM, Wouters BG:Apoptosis, p53 and tumor cell sensitivity to anticancer agents Cancer Res. 1999;59:1391-1399.
  • Zhang Z, Liu Q, Lantry L, Wang Y, Kelloff GJ, Anderson RW, Lubet RA, You M:A germ line p53 mutation accelerates pulmonary tu morigenesis:p53 independent effi cacy of chemop reventive agents green rea or dexamethasone/myo inositol and chemotherapeutic agents taxol and adriamycin. Cancer Res. 2000;60:901-907.
  • Spalding JW, French JE, Stasiewicz S, Furedi-Machacek M, Conner F, Tice RR, Tennant RW:Responses of transgenic mou se lines p53 (1/) and Tg-AC to agents te sted in conventional carcinogenicity bioassays. Toxicol Sci. 2000;53:213-223.
  • Ozaki K, Sukata T, Yamamoto S, Uwagawa S, Seki T, Kawasaki H, Yoshitake A, Wanibuchi H, Koide A, Mori Y, Fukushima S:High susceptibility of p53 (1/) knockout mice in OHBBN urinary bladder carcinogenesis and lack of frequent mutation in residual allele. Cancer Res. 1998;58:3806-3811.
  • Kemp JC, Donehower LA, Bradley A, Balmain A:Reduction of p53 gene dosage does not increase initiation or promotion but enhances malignancy of chemically induced skin cancers. Ce ll. 1993;74:813-822.
  • Xu X, Wagner KU, Larson D, Weaver Z, Li C, Reid T, Henninghausen L, Wynshaw-Boris A, Deng CX:Condition al mutation of BRCA-1 in mammary epithelial cells results in blunted ductal morphogenesis and tumor formation. Nat Genet. 1999;22:37-43.
  • Halberg RB, Katzung DS, Hoff PD, Moser AR, Cole CE, Lubet RA, Donehower LA, Jacoby RF, Dove WF:Tumorigenesis in the multiple intestinal neoplasia mou se:redundancy of negative regulators and specifi city of modifi ers. Proc Natl Acad Sci US A. 2000;28:3461-3466.
  • Laviguer A, Maltby V, Mock D, Rossant J, Pawson T, Bernstein A:High incidence of lung, bone and lymphoid tu mors in mice overexpressing mutant alleles of the p53 oncogene. Mol Cell Biol. 1989;9:3982-3991.
  • Shafarenko M, Mahler J, Cochran C, Kisielewski A, Goldys E, Wiseman R, Goodrow T:Similar incidence of Ki Ras mutations in lung carcinogemas of FVB/N mice and FVB/N mice carrying a mutant p53 transgene. Carcinogenesis. 1997;18:1423-1426.
  • Harvey M, Vogel H, Morris D, Bradley A, Bernstein A, Donehower LA:A mutant p53 transgene accerlerates tumor development in heterozygous but not nullizygous p53 defi cient mice. Nat Genet. 1995;9:305-311.
  • Zhang Z, Lantry LE, Wang Y, Wiseman RW, Anderson AS, Grubbs CJ, Lubet RA, You M:Organ-specific effect of germline p53 mutation on chemical carcinogenesis in mice. A new model for cancer intervention. J Natl Cancer Inst. Su bmitted.
  • Witschi H:Tobacco smoke as a mouse lung carcinogen. Exp Lung Res. 1998;24:385-394.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.